Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for poster presentation at the 42nd Annual Fall Clinical Dermatology Conference® being held October 20-23, 2022, in Las Vegas, NV.
Related news for (NOVN)
- FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
- Novan to Present at the Virtual Investor 2023 Companies to Watch Event
- Novan to Present at the Virtual Investor 2023 Companies to Watch Event
- Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
- Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum